Are Milestone-Based Approaches The Future Of Biopharma And CDMO Partnerships
Are Milestone-Based Approaches The Future Of Biopharma And CDMO Partnerships
Sponsored by:
Sponsored by:
More from Manufacturing
• By
Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?
• By
The French company will start shipping its blockbuster shortly to meet expected strong demand in the 2025–26 RSV season.
• By
Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now
• By
A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.
More from Business
In partnership with Novotech
In partnership with
Insights from Novotech on Evolving Trends Impacting Global Clinical Development
Sponsored by:
Delve into the challenges facing the NHS, from rising medicine costs to supply shortages, and how generics and branded generics can provide solutions for a more sustainable healthcare system
Sponsored by:
Access key stats from biotechs on the latest trends impacting oncology R&D, including therapeutic pipelines and clinical trial challenges, AI/ML, and a future outlook on innovation.